mdxhealth

Mdxhealth is a commercial-stage precision diagnostics company dedicated to providing actionable molecular diagnostic information to personalize the diagnosis and treatment of urologic diseases, primarily focusing on prostate cancer. Their tests are based on proprietary genetic, epigenetic, and other complex molecular technologies, aiming to improve patient outcomes and reduce healthcare costs. The company offers a suite of tests including Select mdx, Confirm mdx, Genomic Prostate Score (GPS), and Resolve mdx, each designed to address specific needs within the urologic care pathway.

Mdxhealth is committed to providing highly accurate and clinically actionable urologic solutions for both patients and healthcare providers. Their tests are designed to be accessible and affordable, with a dedicated patient advocate team available to answer questions about insurance coverage and payment options. They also actively engage in clinical research and collaborate with international academic institutes, medical centers, and organizations to advance the field of urologic diagnostics.

mdxhealth is a commercial-stage precision diagnostics company focused on delivering personalized molecular diagnostic solutions for prostate cancer and other urologic diseases. Their mission is to improve the early detection of aggressive prostate cancer and urologic diseases, provide highly accurate and clinically actionable urologic solutions to inform patient diagnosis and treatment, and improve healthcare economics for payers and providers.

mdxhealth promotes a culture focused on innovation and collaboration, driven by a commitment to improving patient outcomes and advancing the field of urologic diagnostics. They emphasize the importance of scientific rigor and data-driven decision making, while fostering a supportive and collaborative environment for their team.